Apremilast is an inhibitor of phosphodiesterase 4 (PDE4) that is clinically used to treat psoriasis and psoriatic arthritis. Apremilast exhibits anti-inflammatory and immunomodulatory activities, increasing levels of cAMP and IL-10 and decreasing levels of iNOS, IL-23, and TNF-α in vitro and in vivo.
| Cas No. | 608141-41-9 |
|---|---|
| Purity | ≥98% |
| Formula | C23H25N2O7S |
| Formula Wt. | 460.51 |
| IUPAC Name | N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide |
| Melting Point | 156.1°C |
| Solubility | insoluble in water, slightly soluble in ethanol, and soluble in acetone (20mg/mL) |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014 Sep;26(9):2016-29. PMID: 24882690.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. PMID: 22257911.
